Patents Assigned to Hebei Medfaith Pharmaceutical Technology Co., Ltd.
  • Patent number: 10933038
    Abstract: The invention belongs to the technical field of medicines. In particular, the invention relates to use of (benzenesulfonamido) benzamide compounds for inhibiting liver fibrosis, or preventing and/or treating a liver injury, or improving a liver function, or preventing and/or treating a liver disease associated with liver fibrosis, for modulating (e.g. reducing) the content of collagen (e.g. type I collagen) in liver tissue, for modulating (e.g. inhibiting) the activity of COL1A1 promoter in a cell, and for modulating (e.g. inhibiting) expression level of a gene associated with liver fibrosis in a cell.
    Type: Grant
    Filed: November 24, 2016
    Date of Patent: March 2, 2021
    Assignees: Hebei Medfaith Pharmaceutical Technology Co., Ltd., Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences
    Inventors: Hongwei Tian, Xingang Wang, Rongguang Shao, Yucheng Wang, Naren Li, Shi-Ying Cai, Hongwei He, Juxian Wang, Shuangshuang Zhao, Maoxu Ge, Jinfeng Ren
  • Publication number: 20190274979
    Abstract: The invention belongs to the technical field of medicines. In particular, the invention relates to use of (benzenesulfonamido) benzamide compounds for inhibiting liver fibrosis, or preventing and/or treating a liver injury, or improving a liver function, or preventing and/or treating a liver disease associated with liver fibrosis, for modulating (e.g. reducing) the content of collagen (e.g. type I collagen) in liver tissue, for modulating (e.g. inhibiting) the activity of COL1A1 promoter in a cell, and for modulating (e.g. inhibiting) expression level of a gene associated with liver fibrosis in a cell.
    Type: Application
    Filed: November 24, 2016
    Publication date: September 12, 2019
    Applicants: Hebei Medfaith Pharmaceutical Technology Co., Ltd., Institute of Medicinal Biotechnology Chinese Academy of Medical Sciences
    Inventors: Hongwei Tian, Xingang Wang, Rongguang Shao, Yucheng Wang, Naren Li, Shi-Ying Cai, Hongwei He, Juxian Wang, Shuangshuang Zhao, Maoxu Ge, Jinfeng Ren
  • Publication number: 20180333376
    Abstract: The invention belongs to the technical field of medicines. In particular, the invention relates to use of (benzenesulfonamido) benzamide compounds for inhibiting liver fibrosis, or preventing and/or treating a liver injury, or improving a liver function, or preventing and/or treating a liver disease associated with liver fibrosis, for modulating (e.g. reducing) the content of collagen (e.g. type I collagen) in liver tissue, for modulating (e.g. inhibiting) the activity of COL1A1 promoter in a cell, and for modulating (e.g. inhibiting) expression level of a gene associated with liver fibrosis in a cell.
    Type: Application
    Filed: November 24, 2016
    Publication date: November 22, 2018
    Applicants: Hebei Medfaith Pharmaceutical Technology Co., Ltd., Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences
    Inventors: Hongwei Tian, Xingang Wang, Rongguang Shao, Yucheng Wang, Naren Li, Shi-Ying Cai, Hongwei He, Juxian Wang, Shuangshuang Zhao, Maoxu Ge, Jinfeng Ren